Brief: Coiled Therapeutics AO-252 In Phase I Clinical Development In U.S. For Advanced Solid Tumours
03/08/2026 07:35
BRIEF-Coiled Therapeutics AO-252 In Phase I Clinical Development In U.S. For Advanced Solid Tumours Aug 3 (Reuters) - Coiled Therapeutics PLC COIL.L:
COILED THERAPEUTICS - AO-252 IN PHASE I CLINICAL DEVELOPMENT IN U.S. FOR ADVANCED SOLID TUMOURS
COILED THERAPEUTICS - EXPECTS INITIAL SAFETY AND PHARMACOKINETIC DATA FROM NEW FORMULATION IN Q4 2026
COILED THERAPEUTICS - PLANS DOSE-EXPANSION COHORTS IN OVARIAN AND PROSTATE CANCER TARGETING UP TO 30 PATIENTS BY Q4 2026
COILED THERAPEUTICS - NO TREATMENT-RELATED ADVERSE SAFETY FINDINGS IN INITIAL POST-DOSE MONITORING
Source text: ID:nRSC8752Oa
Further company coverage: COIL.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coiled Therapeutics
See all newsRCS - Coiled Therapeutics - Investor Presentation via Engage Investor
RCS - Coiled Therapeutics - Participation in The Small Cap Showcase
Coiled Therapeutics - Director/PDMR Shareholding
Coiled Therapeutics - Interim Results to 30 June 2026
Coiled Therapeutics - Successful Enrolment Completed Across Two Cohorts